Alain Pralong is AMAL’s Chief Operating Officer.
Alain started his career in 2000 at Schering-Plough where he worked on manufacturing Adenovaccine clinical trial material until he moved to Roche in 2004 to manage the transfer of Avastin process manufacturing from Genentech. He then worked at Merck-Serono in the manufacturing of hormones used in the treatment of infertility.
In 2008, Alain became Vice President of Crucell where he led the Global Process Development Department working on various monoclonal antibodies and vaccines until the takeover of Crucell by Johnson & Johnson in 2011. He then worked ad interim as consultant for Pharma Consulting ENABLE GmbH until joining GSK in November 2011. At GSK, Alain worked in Belgium as Vice President for New Product Introduction & Technical Life Cycle Management and in 2014 created the SUTAP (Single-Use Technology Assessment Program) initiative, preparing standards by fostering and driving collaboration of suppliers, end-user, interested third parties and regulatory authorities.
Alain obtained his doctorate in Molecular and Cellular Biology at the University of Berne, Switzerland in 2000. His research into apoptosis was conducted jointly between the University and Novartis. In 2015, Alain has been listed in the 100 most influential people in biopharmaceutical industry issued by The Medicine Maker.